Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital increase.

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.

Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.